Vyome Holdings is a clinical-stage specialty pharmaceutical company focused on developing treatments for immune-inflammatory and rare diseases with no currently approved therapies. Vyome's lead program is VT-1953, a topical gel for malignant fungating wounds (MFW) — non-healing wounds caused when cancer breaks through the skin, producing tissue necrosis, infection, and severe malodor. There are no FDA-approved treatments for MFW. VT-1953's active ingredient is besifloxacin, a fluoroquinolone already FDA-approved as an eye drop, which Vyome reformulated as a topical gel targeting MFW as an orphan drug indication. Phase 2 data showed statistically significant reductions in malodor and pain at Day 14, and Vyome plans to discuss Phase 3 trial design with the FDA in the first half of 2026. Vyome's pipeline also includes VT-1908, a topical eye drop formulation of mycophenolate targeting uveitis, and VB-1953 for inflammatory acne, which is Phase 3-ready but will only advance through a partner. Vyome's core development approach involves taking already FDA-approved molecules, reformulating them topically, and targeting unaddressed orphan indications — a method designed to reduce clinical risk and compress timelines. Vyome generates minimal revenue today, limited to a legacy licensing fee from Sun Pharma covering antifungal products sold in India. Vyome's monetization plan centers on retaining U.S. rights to its lead orphan programs and out-licensing non-U.S. and non-orphan rights to partners.